The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 29, 2022

Filed:

Aug. 28, 2017
Applicants:

Abion Inc., Seoul, KR;

Seoul National University R&db Foundation, Seoul, KR;

Inventors:

Young Kee Shin, Seoul, KR;

Seahyung Lee, Seongnam-si, KR;

Kyoung Song, Seoul, KR;

Ji Hye Lee, Hwaseong-si, KR;

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); A61K 49/16 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); A61P 25/28 (2006.01); A61P 35/04 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61P 25/28 (2018.01); A61P 35/04 (2018.01); G01N 33/68 (2013.01); C07K 2317/34 (2013.01); C07K 2317/515 (2013.01); C07K 2317/565 (2013.01);
Abstract

The present invention provides: an antibody which specifically bonds to human NINJ-1; and a fragment thereof. The antibody or the fragment thereof according to the present invention has very high bonding affinity and bonding specificity with respect to a human NINJ-1 or a homogeneous binding site of the protein, and does not exhibit cross-reactivity with NINJ-1 proteins that are derived from other organisms and have high protein similarity. Accordingly, the present invention provides significant advantages with respect to accuracy and sensitivity and the like, not only in diagnosing disease related to NINJ-1 proteins but also in inhibiting pathological conditions involving NINJ-1 proteins. In particular, the antibody provided according to the present invention has a remarkable effect of inhibiting attachment between immunocytes and human cerebral endothelial cells, and thus has an effect of treating multiple sclerosis.


Find Patent Forward Citations

Loading…